Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?

ABSTRACT: The therapeutic targeting of the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis marked a milestone in the treatment of non-small cell lung cancer (NSCLC), leading to unprecedented response duration and long-term survival for a relevant subgroup of patients affected by non-oncogene-addicted, metastatic disease. However, the biological heterogeneity as well as the occurrence of innate/acquired resistance are well-known phenomena which significantly affect the therapeutic response to immunotherapy. To date, we are moving towards the second phase of the "immune-revolution", characterized by the advent of new immune-checkpoint inhibitors combinations, aiming to target the main resistance pathways and ultimately increase the number of NSCLC patients who may derive long-term cli

SUBMITTER: Passiglia F 

PROVIDER: S-EPMC7872895 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature